Aim: To investigate the effects of onychin on the proliferation of cultured rat artery vascular smooth muscle cells (VSMCs) in the presence of 10% new-born calf serum (NCS). Methods: Rat VSMCs were incubated with onychin 1-50 µmol/L or genistein 10 µmol/L in the presence of 10% NCS for 24 h. The proliferation of VSMCs was measured by cell counting and MTS/PMS colorimetric assays. Cell cycle progression was evaluated by flow cytometry. Retinoblastoma (Rb) phosphorylation, and expression of cyclin D 1 and cyclin E were measured by Western blot assays. The tyrosine phosphorylation of ERK1/2 was examined by immunoprecipitation techniques using anti-phospho-tyrosine antibodies. Results: The proliferation of VSMCs was accelerated significantly in the presence of 10% NCS. Onychin reduced the metabolic rate of MTS and the cell number of VSMCs in the presence of 10% NCS in a dose-dependent manner. Flow cytometry analysis revealed that the G 1 -phase fraction ratio in the onychin group was higher than that in the 10% NCS group (85.2% vs 70.0%, P<0.01), while the S-phase fraction ratio in the onychin group was lower than that in 10% NCS group (4.3% vs 16.4%, P<0.01). Western blot analysis showed that onychin inhibited Rb phosphorylation and reduced the expression of cyclin D 1 and cyclin E. The effects of onychin on proliferation, the cell cycle and the expression of cyclins in VSMCs were similar to those of genistein, an inhibitor of tyrosine kinase. Furthermore immunoprecipitation studies showed that both onychin and genistein markedly inhibited the tyrosine phosphorylation of ERK1/2 induced by 10% NCS. Conclusion: Onychin inhibits the proliferation of VSMCs through G 1 phase cell cycle arrest by decreasing the tyrosine phosphorylation of ERK1/2, and the expression of cyclin D 1 and cyclin E, and sequentially inhibiting Rb phosphorylation.
Introduction
Alterations in vascular smooth muscle cell (VSMC) proliferation plays an important role in the development of the pathological process that underlies restenosis, atherosclerosis, and vascular graft occlusion [1] . Despite intense efforts, no widely effective therapy exits for the prevention of such vascular diseases. Recently some agents have been shown to have potential value by virtue of their abilities to attenuate the proliferation of VSMCs [2] [3] [4] . Among them, genistein (4,5,7-trihydroxyisoflavone), a soybean-derived isoflavone, has been shown to inhibit platelet derived growth factor (PDGF)-induced proliferation and DNA synthesis of aortic smooth muscle cells in stroke-prone spontaneously hypertensive rats [5] . Moreover, epidemiological studies indicate that genistein has beneficial effects on cardiovascular disease [6, 7] , such as lowering total and low density lipoprotein (LDL)-cholesterol levels. More recently, onychin, a new compenent extracted from Onychin lucidum of sinopteridaceae, has attracted our interest because its structure is similar to genistein [8] . Interestingly, our previous results have shown that onychin protects the endothelium-dependent relaxation in rabbit aortic rings and inhibits oxidative stress-induced apoptosis of endothelial cells, which is mediated by increasing NO release, regulating expression of caveolin-1 and activation of mitogen-activated protein kinases (MAPK) [9] [10] [11] [12] [13] . In the present study, we extend our investigation to the effects of onychin on the proliferation of rat VSMCs induced by 10% NCS.
Materials and methods
Materials Male Sprague-Dawley rats were obtained from the Experimental Animal Center of Nanhua University (Hengyang, China). Genistein, elastase, and monoclonal antibodies for α-actins of smooth muscle cells were obtained from Sigma (St Louis, USA). Dulbecco's modified Eagle's medium (DMEM) and NCS were from GibcoBRL (Maryland, USA). The Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay Kit (MTS/PMS) was purchased from Promega (WI, USA). Monoclonal mouse anti-ERK1/2, -pTyr, -cyclin D 1 , -cyclin E, and polyclonal mouse anti-Rb were from Santa Cruz Biotechnology (Santa Cruz, USA).
Cell culture The thoracic aortas were isolated from the 150-200 g male Sprague-Dawley rats and cultured by using a novel enzymatic dispersion method [14] . Briefly, rat aortas were in sterile conditions removed from left subclavian origin to the point of diaphragmatic insertion. The vascular media was digested, and the cells were centrifuged and plated down in prepared flasks. VSMCs were cultivated in DMEM (containing 10% NCS) and in a 5% CO 2 humidified-atmosphere incubator until they displayed as a typical "hill and valley" morphology. The immunohistochemistry staining with a monoclonal antibody against α-actins showed that there were no co-cultured fibroblast cells. VSMCs from 5 to 15 passages were used for experimentation. Before mitogenic stimulation, subconfluent cells were arrested in a quiescent state with DMEM containing 0.1% NCS for 48 h.
Cell count VSMCs (2.5×10 4 ) were plated into a 24-well plate and grown in DMEM supplemented with 10% NCS for 24 h. In some experiments cells were growth-arrested by incubation in DMEM containing 0.1% NCS for 48 h and then exposed to different concentrations of onychin before treatment with 10% NCS for 24 h or 48 h. Genistein (10 µmol/L) was used as the positive control. The cells were then washed with phosphate-buffered saline (PBS), trypsinized, and diluted with isotonic solution. Cells were stained with Trypane blue and the viable cells were counted using a coulter counter.
MTS assay Cell growth was measured by using MTS assay according to the manufacture's instructions. Briefly, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS) were mixed at a ratio of 20:1 immediately before being added to the samples. The MTS/PMS solution (20 µL) was added to each well of the 96-well plate and and the plates were incubated at 37 ºC in a humidified 5% CO 2 atmosphere for 90 min. Absorbance was read at 490 nm using Bio-Tek's Power Wave X reader-assay system (BIO-TEK Instruments, USA). Each sample was read in triplicate.
Flow cytometry Cells were suspended in phosphatebuffered saline (PBS, pH 7.4), and fixed with 70% (v/v) ethanol at -20 ºC for 30 min. After the ethanol was removed, the cells were incubated with PBS containing RNase (172 MU/L) at 37 ºC for 30 min and then stained for 30 min with 0.005% propidium iodide. Fluorescence was measured by using Epics Altra Flow Cytometer (Beckman Coulter Co, USA).
Western blot analysis After treatment, VSMCs were washed twice with cold (4 ºC) PBS (pH 7.4) and harvested on ice in buffer A containing HEPES 20 mmol/L (pH 7.4), EDTA 2 mmol/L, glycerophosphate 50 mmol/L, dithiothreitol 1 mmol/L, Na 3 VO 4 1 mmol/L, 1% Triton, 10% glycerol, leupeptin 1 mg/L, aprotinin 1 mg/L, and phenylmethylsulfonyl fluoride 100 µmol/L. The suspension was incubated on ice for 20 min and vortexed every 5 min. Cell lysates were then centrifuged at 13 000 r/min (Eppendorf centrifuge, Osterode, Germany) for 30 min at 4 ºC. The supernatants were collected, and protein concentration was measured by using the Bio-Rad assay. Forty micrograms of protein (40 µg) weas electrophoresed onto a 12% SDS-PAGE gel and transferred to a polyvinylidene difluoride membrane. The membrane was incubated for 1 h with primary antibodies followed by incubation with second antibodies (horseradish peroxidase-conjugated). Immunoactive bands were visualized using chemiluminescence (AmershamPharmacia Biotech, Piscataway, USA) and densitometric analysis was carried out using an imager and densitometer [15] . Immunoprecipitation Growth-arrested VSMCs were exposed to 0.1% NCS, 10% NCS, 10% NCS+10 µmol/L onychin, or 10% NCS+10 µmol/L genistein for 20 min. Cell lysates were prepared for immunoprecipitation as described previously [16] . Briefly, equal amounts of protein (500 µg) were immunoprecipitated with anti-ERK1/2 polyclonal antibodies overnight at 4 ºC. Immune complexes were collected by incubation with protein A-Sepharose beads for 2 h at 4 ºC. Immunoprecipitates were separated by using SDS-PAGE, and proteins were detected by immunoblotting as described above using anti-pTyr monoclonal antibodies.
Statistical analysis
All values are expressed as mean±SD. Statistical significance was determined by oneway ANOVA. P<0.05 was considered significant.
Results
Effect of onychin on the proliferation of VSMCs Both cell counting and the MTS assay showed that onychin treatment for 24 h or 48 h significantly inhibited VSMC proliferation induced by 10% NCS. The inhibition was concentration-dependent with peak at 10 µmol/L ( Table 1 ). The efficiency of 10 µmol/L onychin treatment for 24 h was similar to that of 10 µmol/L genistein. Therefore we chose 10 µmol/L onychin treating cells for 24 h in the following experiments.
Changes in the VSMC cycle induced by onychin treatment The percentages of G 0 /G 1 or S phase cells in the 10% NCS-stimulated group were 70.0% and 16.4% respectively. In contrast, 10 µmol/L onychin and 10 µmol/L genistein treatments for 24 h led to a significant inhibition of DNA synthesis as evidenced by the fact that the percentages of G 0 /G 1 phase cells increased to 85.2% and S phase cells decreased to 4.3% in the onychin group (Figure 1) .
Decreased Rb phosphorylation induced by onychin treatment The cell cycle progression from G 1 to S phase is usually accompanied by Rb phosphorylation in the late G 1 phase. We therefore examined Rb phosphorylation in VSMCs by using Western blotting with anti-phospho Rb antibody. NCS (10%) stimulated Rb phosphorylation markedly and onychin and genistein inhibited Rb phosphorylation by 70.1% and 58.8%, respectively (Figure 2) .
Onychin lowers the expression of cyclin D 1 and cyclin E To further explore the mechanism by which onychin inhibited Rb, we examined the expression of cyclin D 1 and cyclin E by Western blotting. Results showed that 10% NCS treatment significantly increased both expressions of cyclin D 1 and cyclin E and that pretreatment with onychin 10 µmol/L and genistein 10 µmol/L decreased the NCS-induced expression of these two proteins (Figure 3, 4) .
Effect of onychin on the tyrosine phosphorylation of ERK1/2 ERK1/2 activation is at upstream of cyclins. It has been reported that the protein tyrosine inhibitor genistein is able to inactivate ERK1/2. To investigate whether the inhibitory effect of onychin on ERK1/2 is mediated by tyrosine kinase inhibition, we observed the phosphorylation of the tyrosine residue in ERK1/2. When growth-arrested VSMCs were treated with 10% NCS, a marked time-dependent tyrosine phosphorylation of ERK1/2 was observed, with peak at 20 min (data not shown). Pretreatment with genistein, as well as onychin, significantly inhibited the 10% NCS-induced Growth-arrested VSMCs were exposed to 0.1% NCS, 10% NCS, 10% NCS+10 µmol/L onychin or 10% NCS+10 µmol/L genistein for 24 h. Then cells were fixed with ethanol and incubated with PBS containing Rnase followed by staining with propidium iodide. Fluorescence was determined by using a flow cytometer. tyrosine phosphorylation of ERK1/2, suggesting that onychin might be a potential inhibitor of tyrosine kinase ( Figure 5 ).
Discussion
VSMC proliferation contributes to the remodeling of blood vessels and has been implicated in the pathogenesis of atherosclerosis. Phytoestrogens such as genistein can inhibit the proliferation of VSMC and have been implicated in the suppression of VSMC proliferation in neo-intima formation in vivo. Onychin, which has a similar structure to genistein, has been considered as a candidate for providing several cardiovascular protective effects [9] [10] [11] [12] [13] . To further investigate its actions in vascular biology, in the present study we studied the effect of onychin on the proliferation of rat VSMC induced by 10% NCS. The results showed that 1-50 µmol/L onychin inhibited the proliferation of VSMCs in a concentration-dependent manner, with a peak at 10 µmol/L.
Proliferating cells pass through several cell cycle checkpoints, mainly the G 1 to S and G 2 to M transitions. The former checkpoint is considered to be the most important one in the replication of DNA and mitosis. We thus logically speculate that onychin affects VSMC proliferation via alterations in the cell cycle progression. Indeed our data show that onychin blocks cell cycle progression at the G 1 transition and stops VSMCs entering the S phase from G 0 / G 1 , consequently inhibiting the replication of DNA and the growth of VSMCs. Rb is a key modulator of cell-cycle transit because of its ability to control the G 1 /S-phase transition [17] . Rb activity is related to its ability to modulate the activation of the E 2 F family, which are required for S-phase progression [18] . Cell cycle progression from G 1 to S phase is usually accompanied by Rb phosphorylation, which is induced by the cyclin D 1 -CDK 4 and the cyclin E-CDK 2 complexes in the late G 1 phase. Rb phosphorylation leads to E 2 F release. Conversely, hypophosphorylated Rb sequesters E 2 F and prevents transcription of the E 2 F target genes. Recent evidence indicates that phosphorylated Rb (pRb) inactivation is a key molecular event leading to S-phase commitment at the G 1 restriction point in the cell cycle [19] . Therefore, deregulating pRb inactivation in the G 1 phase becomes a universal mechanism underlying cellular transformation. Recently, Chang et al. showed that a nonphosphorylatable, constitutive active form of murine Rb inhibited VSMC proliferation and reduced neointima formation in injured rat carotid arteries and porcine femoral artery models [20] . Growth factors such as platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor have been shown to induce Rb phosphorylation in quiescent cells entering into the cell cycle [21] . In light of this broad spectrum of activity, Rb is a strong candidate for use as an anti-proliferative agent in a number of disorders that are characterized by inappropriate proliferate responses. To test the possible effects of onychin on Rb phosphorylation, we observed the relative amounts of hypophosphorylated and phosphorylated forms of Rb in VSMCs by using Western blotting. The results showed that onychin decreased the phosphorylation levels of Rb.
Progression through the mammalian mitotic cycle is coordinated by expression and/or activation of multiple holoenzymes composed of a catalytic cyclin-dependent kinase (CDK) and a cyclin-regulatory subunit [22] . Different cyclin/ CDK complexes are temporally activated at specific phases of the cell cycle. Progression through the first gap phase (G 1 ) requires cyclin D-dependent kinase (CDK 4 and CDK 6 ) and cyclin E/CDK 2 activity [22, 23] , which results in Rb hyperphosphorylation. The association of CDK 4 or CDK 6 with D-type cyclins is critical for G1 phase progression, whereas the CDK 2 -cyclin E complex is important for initiation of the S phase. It has been reported that administration of genistein in rats with an acute renal injury decreases ERK activation and cyclin D 1 expression [24] . It has been reported that exposure of VSMC to 10% FCS causes a time-dependent increase in cyclin D1 and cyclin E [25] . In the present study, we also found that 10% FCS up-regulated the expression of cyclin D 1 and cyclin E, and onychin treatment inhibited the effects of NCS.
The MAPK family constitutes a major ubiquitous intracellular signaling system involved in the regulation of cell growth, differentiation, and survival [26] . To date, at least three distinct mammalian MAPKs have been characterized: the extracellular-regulated kinases (ERKs), Jun N-terminal kinases/ stress-activated protein kinase (JNK/SAPK) and p38. Among of them, the mammalian ERKs (ERK1/p44 and ERK2/p42) are generally thought to play a role in cell proliferation and differentiation. ERK1/2 is serine/threonine kinase, which is activated by phosphorylation at both threonine and tyrosine residues. Evidence indicates that phosphorylation of the residues Thr 202/Tyr 204 (for human ERK, or Thr 185/Tyr 187 for bovine ERK) in the conserved Thr/Glu/Tyr ERK sequences is necessary and sufficient for full activation of these enzymes and serves as an indicator of their activation status [27] . In our experiments, we observed an obvious tyrosine phosphorylation of ERK1/2 in the 10% NCS group. Onychin, like genistein, markedly declined the phosphorylation level of tyrosine of ERK1/2.
In summary, onychin inhibits the proliferation of VSMCs through G 1 phase cell cycle arrest by decreasing the tyrosine phosphorylation of ERK1/2, decreasing the expression of cyclin D 1 and cyclin E, and sequentially inhibiting Rb phosphorylation.
